308 related articles for article (PubMed ID: 9815905)
1. Phase I trial of recombinant interleukin 3 before and after carboplatin/etoposide chemotherapy in patients with solid tumors: a southwest oncology group study.
Rinehart J; Margolin KA; Triozzi P; Hersh E; Campion M; Resta D; Levitt D
Clin Cancer Res; 1995 Oct; 1(10):1139-44. PubMed ID: 9815905
[TBL] [Abstract][Full Text] [Related]
2. A Phase I study of granulocyte-macrophage-colony stimulating factor/interleukin-3 fusion protein (PIXY321) following ifosfamide, carboplatin, and etoposide therapy for children with recurrent or refractory solid tumors: a report of the Children's Cancer Group.
Cairo MS; Krailo MD; Weinthal JA; Secola R; Bergeron S; van de Ven C; Blazar BR; Garrison L; Reaman GH
Cancer; 1998 Oct; 83(7):1449-60. PubMed ID: 9762948
[TBL] [Abstract][Full Text] [Related]
3. Phase I/II dose escalation study of recombinant human interleukin-11 following ifosfamide, carboplatin and etoposide in children, adolescents and young adults with solid tumours or lymphoma: a clinical, haematological and biological study.
Cairo MS; Davenport V; Bessmertny O; Goldman SC; Berg SL; Kreissman SG; Laver J; Shen V; Secola R; van de Ven C; Reaman GH
Br J Haematol; 2005 Jan; 128(1):49-58. PubMed ID: 15606549
[TBL] [Abstract][Full Text] [Related]
4. Sequential interleukin-3 and granulocyte-colony stimulating factor prior to and following high-dose etoposide and cyclophosphamide: a phase I/II trial.
Bernstein SH; Fay JP; Christiansen NP; Pinero L; Shah D; Stephan M; Herzig GP
Clin Cancer Res; 1997 Sep; 3(9):1519-26. PubMed ID: 9815838
[TBL] [Abstract][Full Text] [Related]
5. [Phase II clinical trial on China manufactured recombinant human interleukin-11 derivative in the prevention and treatment of chemotherapy-induced thrombocytopenia].
Wang XY; Feng FY; Song ST; Wang HQ; Zhang MH; Liu J; Liu XY; Xu LG; Zhang Y
Zhonghua Zhong Liu Za Zhi; 2005 Jun; 27(6):373-6. PubMed ID: 16117903
[TBL] [Abstract][Full Text] [Related]
6. Phase I trial of subcutaneous interleukin 3 in patients with refractory malignancy: hematological, immunological, and pharmacodynamic findings.
Bukowski RM; Olencki T; Gunn H; McLain D; Budd GT; Sandstrom K; Tuason L; Redovan C; Rayman P; Tubbs R; Resta D; Elson P; Finke J
Clin Cancer Res; 1996 Feb; 2(2):347-57. PubMed ID: 9816178
[TBL] [Abstract][Full Text] [Related]
7. [Effectiveness and safety of recombinant human interleukin-11 in the treatment of chemotherapy-induced thrombocytopenia].
Lei W; Liang J; Chen WG; Ma XZ; Xu M; Du LL
Zhonghua Zhong Liu Za Zhi; 2006 Jul; 28(7):542-4. PubMed ID: 17147124
[TBL] [Abstract][Full Text] [Related]
8. Phase 1 trial of recombinant human interleukin-1 beta (rhIL-1 beta), carboplatin, and etoposide in patients with solid cancers: Southwest Oncology, Group Study 8940.
Rinehart J; Hersh E; Issell B; Triozzi P; Buhles W; Neidhart J
Cancer Invest; 1997; 15(5):403-10. PubMed ID: 9316621
[TBL] [Abstract][Full Text] [Related]
9. Phase I multicenter trial of interleukin 6 therapy after autologous bone marrow transplantation in advanced breast cancer.
Lazarus HM; Winton EF; Williams SF; Grinblatt D; Campion M; Cooper BW; Gunn H; Manfreda S; Isaacs RE
Bone Marrow Transplant; 1995 Jun; 15(6):935-42. PubMed ID: 7581094
[TBL] [Abstract][Full Text] [Related]
10. Phase I and pharmacologic study of sequential topotecan-carboplatin-etoposide in patients with extensive stage small cell lung cancer.
Miller AA; Al Omari A; Murry DJ; Case D
Lung Cancer; 2006 Dec; 54(3):379-85. PubMed ID: 17049403
[TBL] [Abstract][Full Text] [Related]
11. A phase I trial of interleukin 3 (IL-3) pre-bone marrow harvest with granulocyte-macrophage colony-stimulating factor (GM-CSF) post-stem cell infusion in patients with solid tumors receiving high-dose combination chemotherapy.
Sosman JA; Stiff PJ; Bayer RA; Peliska J; Peace DJ; Loutfi S; Stock W; Oldenburg D; Unverzagt K; Bender J
Bone Marrow Transplant; 1995 Nov; 16(5):655-61. PubMed ID: 8547862
[TBL] [Abstract][Full Text] [Related]
12. A phase I clinical, pharmacologic, and biologic study of thrombopoietin and granulocyte colony-stimulating factor in children receiving ifosfamide, carboplatin, and etoposide chemotherapy for recurrent or refractory solid tumors: a Children's Oncology Group experience.
Angiolillo AL; Davenport V; Bonilla MA; van de Ven C; Ayello J; Militano O; Miller LL; Krailo M; Reaman G; Cairo MS;
Clin Cancer Res; 2005 Apr; 11(7):2644-50. PubMed ID: 15814645
[TBL] [Abstract][Full Text] [Related]
13. [Efficiency, safety and tolerability of recombinant human interleukin-3 (rhIL-3) as supportive therapy accompanying dose-intensive carboplatin containing chemotherapy in ovarian cancer with special regard to thrombocytopenia].
Meden H; Fock M; Krauss T; Kuhn W
Zentralbl Gynakol; 1999; 121(8):375-83. PubMed ID: 10486880
[TBL] [Abstract][Full Text] [Related]
14. [Efficacy of once-per-cycle administration pegylated recombinant human granulocyte colony-stimulating factor in chemotherapy-induced neutropenia in a phase I trial].
Yang S; Shi YK; Liu P; Han XH; He XH; Cai YM; Chen ZM
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2006 Jun; 28(3):339-44. PubMed ID: 16900629
[TBL] [Abstract][Full Text] [Related]
15. [Effectiveness and safety of rhIL-11 in the treatment of chemotherapy-induced thrombocytopenia].
Li L; Xu CG; Wang XW; Guo QS; Sun YH; Sun LM
Zhonghua Zhong Liu Za Zhi; 2005 Jun; 27(6):377-9. PubMed ID: 16117904
[TBL] [Abstract][Full Text] [Related]
16. A randomized phase I trial of chronic oral etoposide with or without granulocyte-macrophage colony-stimulating factor in patients with advanced malignancies.
Shaffer DW; Smith LS; Burris HA; Clark GM; Eckardt JR; Fields SM; Weiss GR; Rinaldi DA; Bowen KJ; Kuhn JG
Cancer Res; 1993 Dec; 53(24):5929-33. PubMed ID: 8261405
[TBL] [Abstract][Full Text] [Related]
17. Phase II study of recombinant human interleukin 3 administration following carboplatin and etoposide chemotherapy in small-cell lung cancer patients. SDZ ILE 964 (IL-3) Study.
Kudoh S; Sawa T; Kurihara N; Furuse K; Kurita Y; Fukuoka M; Takada M; Takaku F; Ogawa M; Ariyoshi Y
Cancer Chemother Pharmacol; 1996; 38 Suppl():S89-95. PubMed ID: 8765425
[TBL] [Abstract][Full Text] [Related]
18. Randomized trial of recombinant human interleukin-3 versus placebo in prevention of bone marrow depression during first-line chemotherapy for ovarian carcinoma.
Hofstra LS; Kristensen GB; Willemse PH; Vindevoghel A; Meden H; Lahousen M; Oberling F; Sorbe B; Crump M; Sklenar I; Sluiter WJ; Kiese B; Trope CG; de Vries EG
J Clin Oncol; 1998 Oct; 16(10):3335-44. PubMed ID: 9779710
[TBL] [Abstract][Full Text] [Related]
19. Recombinant human interleukin-3 to dose-intensify carboplatin and cyclophosphamide chemotherapy in epithelial ovarian cancer: a phase I trial.
Veldhuis GJ; Willemse PH; van Gameren MM; Aalders JG; Mulder NH; Mull B; Biesma B; de Vries EG
J Clin Oncol; 1995 Mar; 13(3):733-40. PubMed ID: 7884433
[TBL] [Abstract][Full Text] [Related]
20. Phase I trial of carboplatin, paclitaxel, etoposide, and cyclophosphamide with granulocyte colony stimulating factor as first-line therapy for patients with advanced epithelial ovarian cancer.
Tung N; Berkowitz R; Matulonis U; Quartulli M; Seiden M; Kim Y; Niloff J; Cannistra SA
Gynecol Oncol; 2000 May; 77(2):271-7. PubMed ID: 10785477
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
